<?xml version="1.0" encoding="UTF-8"?>
<p id="Par12">Favipiravir is a wide-spectrum nucleoside antiviral drug developed by FUJIFILM Toyama Chemical Co., Ltd. [
 <xref ref-type="bibr" rid="CR67">67</xref>]. It is a precursor drug that could be metabolized into the active metabolite favipiravir-ribofuranosyl-5′-triphosphate (favipiravir-rtp) in vivo, which has an inhibitory effect on the RNA virus RdRp. The drug’s initial indication was against influenza [
 <xref ref-type="bibr" rid="CR68">68</xref>]. But subsequent studies have shown that the drug has inhibitory activity against almost all RNA viruses, such as West Nile virus, yellow fever virus, enterovirus, and Ebola virus [
 <xref ref-type="bibr" rid="CR69">69</xref>–
 <xref ref-type="bibr" rid="CR72">72</xref>]. On February 15, 2020, favipiravir tablets were marketed in China, and the indication was approved for the treatment of new or recurrent epidemics in adults. Thus, favipiravir became a potential drug for treatment of COVID-19 patients [
 <xref ref-type="bibr" rid="CR73">73</xref>]. In a small-scale clinical trial of COVID-19, favipiravir has shown promising efficacy and low adverse reactions. It has been shown that favipiravir is effective against SARS-CoV-2 (EC
 <sub>50</sub> = 61.88 μmol/L) [
 <xref ref-type="bibr" rid="CR32">32</xref>].
</p>
